Article preview from Medtech Insight - June, 2010
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."
New Avenues in Neuromodulation
by Mary Thompson
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role, including chronic pain, Parkinson's disease, essential tremor and dystonia, epilepsy, gastroparesis, hearing loss, major treatment-resistant depression, obsessive-compulsive disorder, and urinary incontinence. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone this year, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight/Windhover's recently published report, "US Markets for Neurostimulation Products."
Although the neurostimulation device market now has several established segments, such as implantable spinal cord stimulators (SCS) for the treatment of chronic, intractable pain; cochlear implants for profound hearing loss; and deep brain stimulation (DBS) for Parkinson's disease, researchers are also investigating a number of very promising emerging applications, some of which involve large and/or underserved potential patient pools. Among these emerging targets are epilepsy, Alzheimer's disease, blindness, chronic migraines, depression and other psychiatric disorders, obstructive sleep apnea, paralysis, heart failure, and stroke. Moreover, several groups are now working on energy-based extracranial modulation therapies, such as external magnetic stimulation and low- and high-intensity ultrasound, which may one day offer an alternative to surgery and implantable devices for the treatment of certain neurologic conditions.
Continued...
To read this article in its entirety, purchase this article online as a PDF and receive it immediately via email. Or subscribe to "Medtech Insight".
Don't miss Medtech Insight's market report on U.S. Markets for Neurostimulation Products (click to see TOC). For more information or to place orders, contact [email protected] or call +1-714-847-3540
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments